Fresenius stock

FRE · Xetra · EUR

€54.43Change from previous close: +1.51%Absolute change: +€0.81

Close · November 16, 2026

Price history

+11.42% over the period

1 year: from €48.85 (November 17, 2025) to €54.43 (November 16, 2026), +11.42%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€54.43
October 30, 2026€47.79
September 30, 2026€44.75
August 31, 2026€45.24
July 31, 2026€44.52
June 30, 2026€39.97
May 29, 2026€36.27
April 30, 2026€41.25
March 31, 2026€44.32
February 27, 2026€50.90
January 30, 2026€47.21
December 30, 2025€48.98
November 28, 2025€47.33
November 17, 2025€48.85

At a glance

  • The company

    Healthcare company providing products and services for chronically ill patients through pharmaceutical, clinical nutrition, medical technology and hospital operations

  • Latest results

    Quarter to September 30, 2026 · EPS €0.86 (estimate €0.79)

TickerLandia's take on Fresenius

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€35.11
52-wk high€54.35

+0.15% from the 52-week high

Analysts · 14 analysts

Average target€57.73+6.06% vs. price

Buy 13 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Fresenius

Compared with similar companies: strong momentum, low profitability, and low earnings stability.

Financials and price compared with 19 companies in the medical care facilities industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Fresenius is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Fresenius's P/E today is 20.0, above the median of its last 10 fiscal years (13.5; between 10.8 and 26.2 from 2016 to 2025). Fresenius's P/E (trailing 12 months): 19.0, −9% against the median of a group of 10 similar companies (20.8).

P/E compared with its history

Compared with 10 similar companies

Fresenius's metrics compared with similar companies
MetricFreseniusPosition in the groupBand
P/E (trailing 12 months)19.0Middle
Forward P/E13.7Middle
Operating margin9.9%Middle
ROE8.3%Low
Debt/equity0.57Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Fresenius. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€5.95B

Latest quarter · Q2 2026

Net income

€382M

Latest quarter · Q2 2026

Quarterly net margin

6.4%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€30.2B
P/E
19.0
EPS
€2.82
Volume
826.59K
Daily trading
€48.29M
Dividend yield
1.93%
Last ex-dividend on May 25, 2026

How Fresenius is changing

All results
  • Revenue fell 8.8% a year on average over the last 5 years

  • Operating margin rose from 8.5% to 10.0%

  • Profitable in 4 of 5 fiscal years

Returns

Fresenius returns with dividends

€1,000 invested in Fresenius 5 years ago, on November 16, 2021, would be worth €1,619 today with dividends reinvested: +61.93% in total, +10.12% per year. On price alone it would be €1,450 (+44.99%).

PeriodFreseniusDAX€1,000 becomes
1 month+20.75%+5.90%€1,208
6 months+40.28%+11.69%€1,403
Year to date+11.13%+9.23%€1,111
1 year+14.47%+13.39%€1,145
3 years+113.80%+69.45%€2,138
5 years+61.93%+64.64%€1,619
10 years−2.08%+150.85%€979

Over the last 6 months it has done better than 65% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment

The chart in detail

Fresenius: technical analysis

Fresenius is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 31.5% below its all-time closing high (€79.50, June 19, 2017).

Trend
Upward
RSI (14 sessions)
82
Above 70: a strong rise in a short time
vs 200-session average
+22.73%

Active signals

  • New 52-week high.

  • Close above the high of the previous 55 sessions.

  • RSI above 70: the stock has risen a lot in a short time.

    since November 2, 2026

Support and resistance

Price areas where Fresenius has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€54.43
  3. Support€49.31−9.40%2 touches, last on January 27, 2026
  4. Support€48.23−11.39%2 touches, last on August 14, 2026
  5. Support€47.38−12.95%2 touches, last on September 28, 2026

Volatility and risk

Over the last year it has moved less than the DAX.

Beta (1 year) vs DAX
0.60
Volatility (60 sessions, annualised)
25.0%
Largest fall in the last year
−31.98%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Fresenius: seasonality

Average monthly price change over 28 years

+0.7%Jan+1.0%Feb+0.8%Mar+1.2%Apr+1.3%May−0.5%Jun+0.7%Jul+0.3%Aug−0.6%Sep+1.3%Oct+3.9%Nov−0.4%Dec

Over the last 28 years, the strongest month for Fresenius has been November: +3.92% on average, positive in 20 years out of 27. The weakest has been September: −0.60% on average, positive in 13 years out of 28.

Show chart data
MonthAverageMedianPositive years
January+0.67%+1.96%17 of 28
February+1.02%+0.45%15 of 28
March+0.82%+1.24%17 of 28
April+1.24%+1.42%16 of 28
May+1.33%+3.14%17 of 28
June−0.51%−0.42%12 of 28
July+0.66%+0.46%15 of 28
August+0.29%−0.47%12 of 28
September−0.60%−0.26%13 of 28
October+1.27%+0.79%15 of 28
November+3.92%+4.10%20 of 27
December−0.43%+0.14%14 of 28

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Fresenius and its competitors

Hospitals, clinics, physicians and patients with chronic or critical illnesses in North America, Europe, Asia-Pacific, Latin America and Africa are the customers of Fresenius SE & Co. KGaA. Its Fresenius Kabi unit supplies biopharmaceuticals, clinical nutrition, biosimilars, generic injectable drugs, IV fluids, infusion pumps, apheresis machines and cell therapy devices. The Fresenius Helios unit runs hospitals, medical care centers, occupational health and outpatient centers and provides medical diagnostics.

Headquarters
Bad Homburg vor der Höhe, Germany
Employees
179,493
Founded
1912
Chief executive
Michael Sen
Fresenius and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
FreseniusFRE$33.38B9.9%19.0+40.28%
Fresenius Medical CareFME$11.84B10.3%12.1+8.17%
MedicoverMCOV.B$3.95B7.4%39.0+31.17%
Spire Healthcare GroupSPI$1.31B6.2%—+8.87%
TerveystaloTTALO$859.12M8.9%13.6−21.78%
Tenet HealthcareTHC$22.76B19.1%8.37+46.04%

Same industry or related industries, similar size. Compare Fresenius with its competitors · Full profile